



# Psychopharmacology

## *And Substance Abuse News*

Summer 2005

### FROM THE PRESIDENT'S DESK

—James P. Zacny

**G**reetings! First some sundry announcements. As you will notice on the back page of the newsletter, we have added three positions to Division 28 governance. Jennifer Perry from the University of Minnesota is our new, and first, student representative. Jen will have a variety of things on her plate, but one big entrée is identifying training programs associated with psychopharmacology and substance abuse and reaching out to the graduate students in those programs to join our division as Student Affiliates. It is vital to the future of the Division to make a concerted effort to reach out to the next generation of psychopharmacologists and substance abuse researchers/clinicians, so they will call Division 28 "home." Carl Hart, assistant professor at Columbia University, is our new liaison to the Science Directorate. His duties will include, but not be limited to, responding to requests from the Science Directorate for help/information on issues related to psychopharmacology and substance abuse, monitoring the awards programs that APA and the Science Directorate run to ensure that our division puts forth candidates on a regular (and not sporadic) basis, and working with the Directorate in trans-

lating some of the research our divisional members do into lay language so "the average person on the street" can get a better grasp of what we do and how it benefits society (see [www.psychologymatters.org](http://www.psychologymatters.org)). James Rowlett from the New England Primate Research Center, who currently is a member of CARE (Committee on Animal Research and Ethics), has agreed to be our liaison to the committee for this year. This was a long-time position in the Executive Committee that for one reason or another got lost in the shuffle. It is obviously a vital committee to many members of the division, and I am glad James will keep us informed of committee activities relevant to the divisional membership.

The divisional programming at this year's convention looks exceptionally good, and I would like to thank Diana Walker for the quality and quantity of work in getting it organized. In interacting with Diana, I certainly gained a greater appreciation for the duties and challenges of being a Program Chair. There are many exciting elements to the programming, and one of note is that Nora Volkow and T.K. Li, Directors of NIDA



*Continued on page 2*

and NIAAA, respectively, will be receiving APA Presidential Citations at the convention. The citations are to be given in appreciation of their leadership at institutes of the NIH that fund the majority of research programs conducted by Division 28 and Division 50 members. I would like to thank Steven Breckler, Executive Director for Science at APA, for playing a major role in helping these awards come about. Special thanks are also given to Ron Levant, APA President.

It is also exciting to note that Hendree Jones will be receiving the prestigious APA Award for Distinguished Scientific Early Career Contribution to Psychology. Hendree, Associate Professor at the Johns Hopkins University, has made major contributions in creating and modifying treatments for pregnant drug-dependent women. She is one of the first researchers to examine contingency management procedures in pregnant women, and has also pioneered the examination of the use of buprenorphine for treating pregnant opioid-dependent women.

I would like to mention one initiative that Joshua Lile, our membership chair, and I have undertaken. There are a number of scientists in this country who conduct research entirely consistent with the mission of our division, who for one reason or another are not members of APA. The bylaws of our division allow scientists who have interest and/or expertise in the research areas and activities of the division to join the division as Affiliates. Traditionally we have not proactively sought scientists out and asked them to become affiliates. However,

our division is one of the first organizations to have had as its mission the investigation of drugs and behavior. Our goal is for those scientists and clinicians who subscribe to this mission to be in the same "community," in an organization (Division 28) specifically formed for this purpose. This year, with the help of current and former members of the Executive Committee, we have selected a number of scientists doing research on drugs and behavior and have asked them to become affiliates. Hopefully at August's business meeting we will be presenting a number of people for Affiliate status so a formal vote can be taken by the membership. Because Josh and I, as well as the other members of the Executive Committee, want this to be an ongoing as well as membership-wide process, we would encourage you to forward names of scientists that you feel should be in our division to Joshua Lile (jalile@uky.edu). Ultimately I hope the scientists who become Affiliates eventually become members of APA and the division. In my last newsletter column later this year, I will give you an update on how we are faring with our Affiliate recruitment efforts.

I wanted to give you an update on what is currently known (at the time of this writing on July 6) about the Drug Addiction Treatment Expansion Act (DATEA, H.R. 869). This act will do away with language in the original act that imposed a 30-patient cap on group practices in prescribing buprenorphine for opioid dependence. By removing the 30-patient limit imposed on group practices, access to treatment will be expanded at this critical time when there are more patients seeking treatment for opioid

dependence than there are slots. The bill has recently been reported out of both the Energy and Commerce Committee and the Judiciary Committee in the U.S. House of Representatives. The Energy and Commerce Committee has already filed its report on H.R. 869, and it is likely that the Judiciary Committee will file a similar report on or about July 11, 2005. It has been suggested the bill could be voted on by the full House soon thereafter. So things are looking good! A number of organizations, including the American Psychological Association, have co-sponsored the bill, and these organizations will be listed in the Judiciary Committee report.

Finally, I have announced the winners of this year's division elections via e-mail but realize not all of you may be on the listserv (but I would encourage you to sign up!). Suzette Evans was elected as President for 2007; Nancy Petry was elected as Member-at-Large from 2006–2008, and Nancy Ator was elected as APA Divisional Council Representative, also from 2006–2008.

I hope to see many of you in Washington in August!

## NEW EDITORIAL BOARD

Announcing the new editorial Advisory Board for Psychopharmacology and Substance Abuse

Hendree Jones, Ph.D.

Nancy Petry, Ph.D.

Mark Reilly, Ph.D.

Karen Saules, Ph.D.

This board will help Dr. Roll shape the contents and format of the newsletter for the next year.



## DIVISION 28 MEMBERSHIP

On behalf of the Executive Committee of the Division of Psychopharmacology and Substance Abuse in the American Psychological Association, I, as Division Membership Chair, and Jim Zacny, President, would like to encourage participation in our Division. If you are currently involved in Division 28, I would like to encourage you to upgrade your membership, as appropriate, and to invite your colleagues to join. Our members include international and national experts in various areas of psychopharmacology and substance abuse, including a former director of the National Institute on Drug Abuse, the current president of the College on Problems of Drug Dependence and the current APA Director of Science Policy. The Division, organized in 1966, is one of the first organizations to have had as its mission the investigation of drugs and behavior. Our goal is for those scientists and clinicians who subscribe to this mission to be in the same community, in an organization specifically formed for this purpose.

Several membership opportunities exist within Division 28 for current members of APA, as well as

non-members. For current members of APA, there are three classes of membership, including Fellows, Members, and Associate Members. Fellows are nominated by the Division 28 Executive Committee and are those individuals who have attained Fellows status within APA, have been engaged in independent research in the area of drugs and behavior for five years subsequent to obtaining the doctoral degree, and have made significant and sustained contributions to understanding drugs and behavior. Members and Associate Members of Division 28 are Members and Associate Members of APA, respectively, and have expressed an interest in the area of drugs and behavior.

Individuals who have interest and/or expertise in the research areas and activities of the division, but are not members of APA, are also welcome to join our Division. The classes of membership for non-APA members are Affiliates and Corporate Affiliates. Affiliates are those individuals who are Student Affiliates of APA, other graduate students actively involved in research or clinical psychopharmacology, and persons who have qualifica-

tions in psychology or in neuroscience, pharmacology or physiology, and whose work is related to advancing a fuller understanding of drugs and behavior. Corporate Affiliates are any firm, association, corporation, or institution, or one or more subdivisions thereof, that supports the Division by financial contribution.

If you, or one of your colleagues, are interesting in joining or upgrading your membership, either e-mail me (jalile2@uky.edu) or complete the membership application, which can be found at [www.apa.org/divisions/div28/brochure.html](http://www.apa.org/divisions/div28/brochure.html). Dues are nominal (\$18/year) and members receive our newsletter and are put on our listserv. At the annual APA convention this August, the Executive Committee of the Division and divisional members at the business meeting will consider your application. You will be notified shortly thereafter.

I hope you give serious consideration to our invitation and look forward to hearing from you in the near future.

Sincerely,  
Joshua Lile



# HELP YOURSELF, HELP DIVISION 28, HELP APA

## Vote for APA President

Why vote for APA president: The president of APA is the most influential individual in APA. This is the one person who can have the most influence on the things that you want APA to do for you and for members of your group/s.

As a member of Division 28, you may be looking for leaders who have a large understanding of the needs of psychologists who deal with psychopharmacological issues. So how do you decide which candidate/s will best fit those needs? Often members who are not involved in APA governance think that they do not know the candidates and it does not matter if they vote. The next paragraph is for you.

How to vote for APA president: In this case, it is really how to choose your candidates. First, decide which candidates to include on your ballot and then to rank order those candidates. In APA, one does not just vote for one candidate and think that is

it. It is important to rank the candidates so that if your number one candidate is dropped from the ballot on the first round, then your second choice receives your vote. If no one receives a majority of the votes on the second round and your number two candidate is dropped, then your third choice receives your vote. Thus, ranking the candidates is important.

So which candidates should you choose? I find the best method, if you do not know the candidates, is to read what they have done. What they say they will do is less useful, because the president must be everything to all members so all say they support academia, practice, and science. But what have they done? If they have spent most of their career in academia, then they will likely support the things that academics want. The same can be said for practice activities, and for research activities. Thus, I pay much more attention to what

candidates have done than to what they say.

There are several places to learn about the candidates:

- (1) the APA Monitor on Psychology devotes space for several months to answers to specific questions posed to the candidates;
- (2) also, most of the candidates have a Web site, such as those of Brehm ([www.brehm4apa.com](http://www.brehm4apa.com)) and Overmier (<http://www.psych.umn.edu/faculty/overmier/biography.htm>); and
- (3) another choice is to do a Google search on each candidate's name.

For whatever candidates you choose, the most important thing is to vote as soon as the ballot arrives in October.

*—MaryLou Cheal, Fellow of Division 28 and President of the Coalition for Academic, Scientific, and Applied-Research Psychology of APA Council*

### EDITORIAL POLICY

*Psychopharmacology and Substance Abuse News* is a thrice-yearly publication of Division 28. It is devoted to keeping its members informed about the activities of Division 28 and to news and comments concerning all aspects of psychopharmacology and substance abuse. Articles, comments, announcements, and advertisements should be sent to John Roll at [johnroll@wsu.edu](mailto:johnroll@wsu.edu). The deadline for the winter issue is November 1, 2005.

7/05 109831



## 2005 DIVISION AWARD WINNERS TO BE HONORED AT CONVENTION AND IN ECP

Dr. Nancy Mello, the 2005 Brady-Schuster Award winner and incoming Editor for *Experimental and Clinical Psychopharmacology*, has instituted an annual "Awards Issue" for the journal. This year's Awards Issue, due this fall, will include review pieces by the 2004 and 2005 honorees based on their award-winning work. As a preview of both that issue and this year's Awardee lectures at the APA Convention on Thursday, August 18, biographical paragraphs on each of the honorees are presented below.

**Outstanding Dissertation  
Award sponsored by Friends  
Research Institute: Andrew C.  
Barrett, Ph.D.**

During graduate school at the University of North Carolina at Chapel Hill, Dr. Andrew Barrett conducted rodent behavioral studies on the antinociceptive and discriminative stimulus effects of opioids. His dissertation research involved evaluating sex

differences in opioid antinociception. One critical factor in determining the behavioral effects of opioids is relative efficacy, and the use of opioid efficacy as a tool to evaluate sex differences in antinociception is a common theme throughout Dr. Barrett's research. In his postdoctoral work, Dr. Barrett is continuing his interests in behavioral pharmacology at McLean Hospital, Harvard Medical School, where he is currently conducting studies on cocaine self-administration and medications development for cocaine addiction. In his award lecture, Dr. Barrett will be discussing findings from his dissertation research. First, concepts of opioid relative efficacy, derived from classical receptor theory, will be discussed. Second, experiments will be described in which opioid efficacy was systematically manipulated as an independent variable to probe underlying sex differences in opioid system function. Third, sex differences will

be described in the context of other variables, such as the drug history of the animal, genotype, and nociceptive stimulus modality, as well as the interaction of opioid efficacy with these variables.

**Wyeth Young Psychopharmacologist Award: Cynthia A. Conklin, Ph.D.**

Dr. Conklin won the 2005 APA Division 28 Wyeth Young Psychopharmacologist Award for her research on subjective, physiological, and behavioral reactivity to drug-related cues in adult smokers. She received her undergraduate degree in psychology from the University of Delaware in 1994 and her Ph.D. in Clinical Psychology from Purdue University in 2001. She is now an Assistant Professor of Psychiatry at Western Psychiatric Institute and Clinic at the University of Pittsburgh. Dr. Conklin has conducted both animal conditioning and human *Continued on page 6*

### DIVISION 28 THANKS THE FOLLOWING FOR THEIR CONTINUED SUPPORT:

**Merck**

(corporate membership support)

**Wyeth Research**


(Young Psychopharmacologist Award support)

**Friends Research Institute, Inc.**

(Dissertation Award support)

**MED Associates**

(Brady-Schuster Award support)



cue-reactivity addiction research. Her talk will focus on recent work from her nicotine dependence laboratory aimed at studying the impact of environmental contexts on smokers' cue-reactivity. She will present the rationale and methods for examining cue-reactivity in addicts, novel techniques for studying contexts in the laboratory, and results from a recent series of studies with smokers incorporating environmental context cues. Overall, this work demonstrates that, like more traditionally studied proximal smoking cues (e.g., lit cigarettes, lighters), exposure to more distal cues, in particular environmental contexts associated with smoking, can alone function as conditioned stimuli capable of evoking strong reactivity from abstinent smokers. Moreover, such reactivity can be enhanced if environmental context cues are personalized using new techniques designed in her laboratory.

The implication of these findings for human extinction research and behavioral addiction treatments will be discussed.

**Brady-Schuster Award sponsored by MED Associates: Nancy K. Mello, Ph.D.**

Dr. Mello is Professor of Psychology (Neuroscience), in the Department of Psychiatry at Harvard Medical School. She is also Co-Director of the Alcohol and Drug Abuse Research Center (ADARC) and Director of the Behavioral Science Laboratory at McLean Hospital. After earning a Ph.D. in Clinical Psychology at Pennsylvania State University, Dr. Mello was a postdoctoral trainee in physiology, then in psychology with Dr. B.F. Skinner at Harvard University. Dr. Mello then joined the Stanley Cobb Laboratories for Psychiatric Research at Massachusetts General Hospital. Subsequently, Dr. Mello directed the first Intramural Research Program at what is now the National Institute on Alcohol Abuse and Alcoholism. She

was also a Research Consultant to the Special Action Office for Drug Abuse Prevention of the Executive Office of the President. Dr. Mello then returned to Harvard Medical School, and with Dr. Jack H. Mendelson, founded the ADARC. Dr. Mello has published over 350 scientific papers and 11 books and monographs, and was appointed incoming Editor for *Experimental and Clinical Psychopharmacology* in 2005. Recently, Dr. Mello has focused on the analysis of the interactions between cocaine and opioids, and medication-based treatment of heroin + cocaine "speedball" self-administration. In addition, she is currently studying the interactions between abused substances and the hormonal milieu. Dr. Mello's award lecture, entitled "Behavioral Science—Ever Changing Directions," will summarize her behavioral science-based research on issues ranging from visual function and drug abuse to the hormonal correlates of cocaine and nicotine.

## AWARD FOR DISTINGUISHED SERVICE TO PSYCHOLOGICAL SCIENCE

The APA Board of Scientific Affairs (BSA) is soliciting nominations for the Award for Distinguished Service to Psychological Science. This award recognizes individuals who have made outstanding contributions to psychological science through their commitment to a culture of service. Award recipients will receive an honorarium of \$1,000. The deadline for nominations is August 25, 2005.

Nominees will have demonstrated their service to the discipline by aiding in association governance; serving on boards, committees, and various psychological associations; editing journals; reviewing grant proposals; mentoring students and colleagues; advocating for psychological science's best interests with state and federal lawmakers; and promoting the value of psychological science in the public eye. Nominees may be involved in one service area, many of the areas, or all of the service areas noted above. An individual's service to the discipline and not a person's scholarly achievements are the focus of this award.

Additional information and instructions on submitting applications can be found on the APA Science Directorate Web site: [www.apa.org/science/serv\\_award.html](http://www.apa.org/science/serv_award.html).

Congratulations to  
**HENDREE JONES, Ph.D.**

Winner of this  
year's prestigious

**APA AWARD FOR  
DISTINGUISHED  
SCIENTIFIC  
EARLY CAREER  
CONTRIBUTION  
TO PSYCHOLOGY**



## DIVISION 28 EVENTS AT APA 2005

### Wednesday, August 17

6-7:50PM

Executive Committee Meeting  
Renaissance Washington, D.C., Hotel: Meeting Room 7

### Thursday, August 18

8-8:50AM

Award Ceremony: *Outstanding Dissertation Award Sponsored by Friends Research Institute and Wyeth Young Psychopharmacologist Award*  
Washington Convention Center: Meeting Room 147A

#### Cochairs, Presenters, and Titles:

Outstanding Dissertation Award (Chair: Drake Morgan): Andrew Barrett: *Low-Efficacy Opioids—Implications for Sex Differences in Opioid Antinociception*

Wyeth Young Psychopharmacologist Award (Chair: Kenneth A. Perkins): Cynthia Conklin: *Craving to Smoke—The Impact of Mood, Environment, and People*

9-9:50AM

Award Ceremony: *Brady-Schuster Award Sponsored by MED Associates*  
Washington Convention Center: Meeting Room 151A  
Chair: Jane Acri

#### Presenter and Title:

Nancy Mello: *Behavioral Science: Ever-Changing Directions*

10-11:50AM

Symposium: *Nicotine Psychopharmacology and Policy—A Look Behind and a Look Ahead*  
Washington Convention Center: Meeting Room 146B  
Cochairs: Jack E. Henningfield & Ian Stolerman

#### Presenters and Titles:

Victor J. DeNoble & Paul C. Mele: *Nicotine Research at Philip Morris: Discoveries Suppressed and Its Consequences*

Athina Markou: *Current Understanding of Nicotine Self-Administration and Dependence in Animals*

Jed E. Rose: *The Importance of Conditioning and Sensorimotor Factors in Tobacco Addiction*

Maxine L. Stitzer: *Treatment Overview: The Role of Behavioral Pharmacology*

Jack E. Henningfield: *Psychopharmacology Research Implications for National and Global Tobacco Regulation*  
Discussant: Mitchell Zeiler

12-1:50PM

Social Hour: *DeNoble-Mele Reception*  
Renaissance Washington, D.C., Hotel: Meeting Rooms 12, 13, and 14

2-3:50PM

Symposium: *Behavior Genetics of Drug Abuse in the Molecular Genetics Era*

Washington Convention Center: Meeting Room 103A  
Cochairs: Joni L. Rutter & Kevin Conway

#### Presenters and Titles:

Carol Prescott: *Genetic Epidemiology of Substance Use Disorders*

Robert A. Zucker: *Relationships Between Genes, Brain, and Behavioral Risk for Drug Abuse: Preliminary Results*

George Uhl: *SNPs, Chips, and Convergent Molecular Genetics of Human Addiction Vulnerability*

Caryn Lerman: *Genetic Influences on Smoking Persistence and Response to Pharmacotherapy*

4-4:50PM

Business Meeting  
Grand Hyatt Washington Hotel: Constitution Ballroom C

7-8:50PM

Symposium: *Drugs, African Americans, HIV, and Criminalization—Breaking the Cycle?*  
Washington Convention Center: Meeting Room 147A  
Chair: Lula A. Beatty

#### Presenters and Titles:

Faye S. Taxman: *Churning and Legitimacy: Disproportionate Representation of Blacks in the Criminal Justice System*

Claire E. Sterk: *Black Women Drug Users, HIV/AIDS, and Criminal Justice Involvement*

Karen Freeman-Wilson: *Making It Plain: Ensuring the Translation from Research to Practice*

Vickie M. Mays: *Black Men, Drugs, HIV, and Crime: Who's to Blame?*

Discussant: Dionne J. Jones

### Friday, August 19

8-9:50AM

Symposium: *Development, Evaluation, and Dissemination of Family-Based Adolescent Substance Abuse Treatments*  
Washington Convention Center: Meeting Room 150A  
Chair: Jody L. Kamon

#### Presenters & Titles:

Jody L. Kamon: *Efficacy of a Contingency-Management Treatment for Adolescent Substance Abuse*

Susan H. Godley: *Family Sessions Impact on CYT Process and Outcome*

Howard A. Liddle: *Mining the Connections Among MDFT Treatment Development, Evaluation, and Dissemination*

Bradley Donohue: *Manual Development in Family*

*Behavior Therapy for Drug Abuse*

Discussant: Nathan H. Azrin

10-11:50AM

Cross-Cutting Event: *Comorbidity and Beyond: Substance Use, Health, and Mental Health*  
Washington Convention Center: Meeting Room 146B  
Chair: Linda Sobell

#### Presenters and Titles:

Nancy Piotrowski: *Comorbidity and Psychological Practice: Does One Size Fit All?*

Matthew Nessel: *The Psychological and Medical Sequelae of Substance Abuse: A Primary Care Perspective*

Mark Sobell: *Implications of Substance Use for Treating Other Disorders*

Kate Carey: *Substance Abuse with Severe Mental Illness: What Do We Need to Do Differently?*

Christina Meade: *Substance Abuse and HIV Risk Behavior Among Adults with Severe Mental Illness: Implications for Risk Reduction Interventions*  
Discussant: Linda Sobell

2-2:50PM

Fellows Addresses I: *Addresses by 2004 New Fellows*  
Renaissance Washington DC Hotel: Renaissance Ballroom West A  
Chair: Suzette M. Evans

#### Presenters and Titles:

Donald M. Dougherty: *Effects of Combined Alcohol and L-Tryptophan Depletion/Loading on Impulsive Behavior*

Mark T. Fillmore: *Drug Effects on Attention: Learning from Cognitive Models*

Theresa D. Hernandez: *Learning from What the Brain Already Knows*

Friedbert Weiss: *Compulsive Drug-Seeking and Vulnerability to Relapse: Novel Pharmacological Treatment Targets*

3-3:50PM

Presidential Address  
Renaissance Washington, D.C., Hotel: Renaissance Ballroom West A  
Chair: Alan J. Budney

#### Presenter and Title:

James P. Zacny: *Prescription Opioid Nonmedical Use and Abuse: We Are Still on the Learning Curve*

4-5:50PM

Award Ceremony: *2005 American Psychological Association and American Psychological Foundation Awards*. One of the awards, the APA Distinguished Scientific Award for Early Career Contribution to Psychology, in the area of Applied Psychology, will be presented to Hendree Jones, Ph. D., a Member of Division 28.  
Renaissance Washington, D.C., Hotel: Grand Ballroom North

Continued on page 8



Events at APA 2005 *Continued from page 7*

**4-6:50PM**

Poster Session, Social Hour, Award Ceremony:  
*NIDA/NIAAA Early Career Investigators Poster Session & Social Hour and Presentation of APA Presidential Citations to the Directors of NIDA (Nora Volkow, Ph.D.) and NIAAA (T.K. Li, Ph.D.)*  
Renaissance Washington, D.C., Hotel: Grand Ballroom South

**Saturday, August 20**

**8-8:50AM**

Fellows Addresses II: *Addresses by 2005 New Fellows*  
Washington Convention Center: Meeting Room 140B  
Chair: Suzette M. Evans

**Presenters and Titles:**

Christopher S. Martin: *Diagnosis and Clinical Course of Adolescent-Onset Alcohol and Substance-Use Disorders*

Nancy M. Petry: *Pathological Gambling: Comorbidity and Treatments*

Tamara L. Wall: *Genetic Associations of Alcohol and Aldehyde Dehydrogenase with Alcohol-Related Behavior*

**9-9:50AM**

Workshop: *Deciphering the NIH Roadmap—Directions to Success in Grant Funding*  
Washington Convention Center: Meeting Room 151B, Cochairs/Presenters: *Judy M. Cole & Melissa W. Racioppo*

**10-10:50AM**

Poster Session: *Division 28 and Division 50 Poster Session*  
Washington Convention Center: Halls D and E

**12-1:50PM**

Symposium: *Adolescent Brain Development—What Does It Have to Do With Cognitive Processes?*  
Washington Convention Center: Meeting Room 152A, Cochairs: Minda R. Lynch, L.R. Stanford, & Teri Levitin

**Presenters and Titles:**

Beatriz Luna: *Cognitive Control of Behavior and the Immature Adolescent Brain*

Deborah A. Yurgelun-Todd: *Neurobiological Correlates of Inhibitory Processing in Adolescents*

Jay Giedd: *Brain Development During Adolescence*

Jim Bjork: *Reward Processing in the Adolescent Brain*

**Sunday, August 21**

**8-9:50AM**

Symposium: *Addiction Research in Residential Treatment—Emerging Findings with Special Populations*  
Washington Convention Center: Meeting Room 102B, Chair: James L. Sorenson

**Presenters and Titles:**

James L. Sorenson: *Methadone Maintenance Patients in the Therapeutic Community*

Samuel Ball: *Psychotherapy Enhancement for TC Retention*

Suzanne Wenzel: *Improving Quality of Care in the Therapeutic Community*

Stanley Sacks: *MTC for Offenders with MICA Disorders: Finding and Future Directions*

JoAnn Y. Sacks: *Trauma-Specific Interventions for Women in Residential Treatment*  
Discussant: George De Leon

**10-11:50AM**

Symposium: *Alcoholism, Adherence, and Outcomes—Optimizing Psychosocial and Pharmacologic Therapies*  
Washington Convention Center: Meeting Room 102B  
Chair: Helen Pettinati

**Presenters and Titles:**

Nancy M. Petry: *Strengths and Weaknesses of Psychosocial Treatment Strategies*

Henry R. Kranzler: *Emerging Treatment Options for Alcoholism*

Helen M. Pettinati: *Nonadherence in the Treatment of Alcoholism and Its Negative Impact on Outcomes*  
Discussant: A.T. McLellan

**12-1:50PM**

Symposium: *Neurobiological Aspects of Drug Addiction—Implications for Treatment*  
Washington Convention Center: Meeting Room 102B  
Cochairs: David Shurtleff & Lisa Onken

**Presenters and Titles:**

Michael Otto: *Exposure Treatments for Substance Dependence: Advances in the Conceptualization and Enhancement of Extinction Learning*

David G. Gilbert: *Brain, Cognitive, and Affective Indices of Smoking Withdrawal and Nicotine Replacement Therapy: Duration of Effects and Individual Differences in Response*

Rita Goldstein: *Neuropsychological Impairment in Drug Addiction and Its Association with Prefrontal Cortical Activity*

William Fals-Stewart: *Cognitive Rehabilitation with Drug Abusers*

---

**Division 50 Program Summary, APA 2005**

Symposium: *Research on Organizational Effectiveness in Substance Abuse Treatment*

**8/18 Thu: 8:00 AM–9:50 AM**

Washington Convention Center, Meeting Room 102B, Chair: Thomas F. Hilton, Ph.D.

Discussion: *Legal Issues Affecting Services for Persons With Substance Use Disorders*

**8/18 Thu: 10:00 AM–11:50 AM**

Renaissance Washington, D.C., Hotel, Renaissance Ballroom West A, Chair: Richard Lopez, Ph.D., J.D.

Symposium: *Adolescence—Integrating Research on Development and Addiction*

**8/18 Thu: 10:00 AM–11:50 AM**

Washington Convention Center, Meeting Room 101  
Chair: Sandra A. Brown, Ph.D.

Symposium: *From Student to Professional—Establishing an Addictions-Focused Career*

**8/18 Thu: 12:00 PM–1:50 PM**

Washington Convention Center, Meeting Room 102B, Chair: Keith J. Morgan, Ph.D.

Symposium: *Behavior Genetics of Drug Abuse in the Molecular Genetics Era*

**8/18 Thu: 2:00 PM–3:50 PM**

Washington Convention Center, Meeting Room 103A, Cochairs: Joni Rutter, Ph.D. & Kevin Conway, Ph.D.

Symposium: *Alcohol and Drug Intervention Alternatives—Considerations of Efficacy and Cost*

**8/18 Thu: 3:00 PM–3:50 PM**

Washington Convention Center, Meeting Room 204C  
Chair: Bradley D. Olson, Ph.D.

Symposium: *Rural Substance Abuse—New Methods, New Findings, New Funding*

**8/18 Thu: 7:00 PM–8:50 PM**

Washington Convention Center, Meeting Room 151A  
Chair: Laurie Roehrich, Ph.D.

Symposium: *Drugs, African Americans, HIV, and Criminalization: Breaking the Cycle?*

**8/18 Thu: 7:00 PM–8:50 PM**

Washington Convention Center, Meeting Room 147A  
Chair: Lula A. Beatty, Ph.D.

Symposium: *Evidence-Based Practice in the Treatment of Addictive Behavior Problems*

**8/19 Fri: 8:00 AM–9:50 AM**

Washington Convention Center, Meeting Room 152A  
Chair: Nancy A. Piotrowski, Ph.D.

Symposium: *Comorbidity and Beyond: Substance Use, Health, and Mental Health*

**8/19 Fri: 10:00 AM–11:50 AM**

Washington Convention Center, Meeting Room 146B  
Chair: Linda C. Sobell, Ph.D.

Discussion: *Building and Understanding a Collegiate Substance-Use Recovery Community*



**8/19 Fri: 10:00 AM–11:50 AM**  
Renaissance Washington, D.C., Hotel, Renaissance Ballroom West A  
Co-chairs: Kitty S. Harris, Ph.D. & Alan S. Reifman, Ph.D.

Symposium: *Dynamic Models of the Role of Self-Regulation in Addictive Behavior*

**8/19 Fri: 12:00 PM–1:50 PM**  
Renaissance Washington, D.C., Hotel, Renaissance Ballroom West A  
Chair: Mark Muraven, Ph.D.

Invited Symposium: *Contributions of Alcohol Research to Behavioral Science*

**8/19 Fri: 2:00 PM–3:50 PM**  
Washington Convention Center, Meeting Room 145A  
Chair: Mark S. Goldman, Ph.D.

Social Hour / Young Investigator's Poster Session [Joint Session with Division 28]

**8/19 Fri: 4:00 PM–6:50 PM**  
Renaissance Washington, D.C., Hotel, Grand Ballroom South  
Sponsored by NIAAA and NIDA

Symposium: *United States—The Netherlands Binational Collaboration on Drug Abuse*

**8/20 Sat: 8:00 AM–8:50 AM**  
Washington Convention Center, Meeting Room 156  
Co-chairs: Eve Reider, Ph.D. & Beverly A. Pringle, Ph.D.

Poster Session [Joint Session with Division 28]

**8/20 Sat: 10:00 AM–10:50 AM**  
Washington Convention Center, Halls D & E  
Chair: Nancy A. Piotrowski, Ph.D.

**Poster Session**

**8/20 Sat: 11:00 AM–11:50 AM**  
Washington Convention Center, Halls D & E  
Chair: Laurie Roehrich, Ph.D.

Presidential Address [Carlo C. DiClemente, Ph.D.]: *Ready or Not: Changing Perspectives on Addiction Programs, Providers, Policies, and People*

**8/20 Sat: 12:00 PM–12:50 PM**  
Renaissance Washington, D.C., Hotel, Renaissance Ballroom West A  
Chair: Marsha E. Bates, Ph.D.

**Business Meeting**

**8/20 Sat: 1:00 PM–1:50 PM**  
Renaissance Washington, D.C., Hotel, Renaissance Ballroom West A

Symposium: *Translational Research on Smoking Cessation—Types I and II*

**8/20 Sat: 2:00 PM–3:50 PM**  
Grand Hyatt Washington Hotel, Independence Ballrooms D and E  
Chair: Beverly A. Pringle, Ph.D.

Symposium: *Using Assessment to Improve Drug Abuse Treatment for Offender Populations*

**8/21 Sun: 8:00 AM–9:50 AM**  
Washington Convention Center, Meeting Room 101  
Chair: Redonna K. Chandler, Ph.D.

Symposium: *Meeting Treatment Needs of Girls and Women With Co-Occurring Conditions*

**8/21 Sun: 10:00 AM–11:50 AM**  
Washington Convention Center, Meeting Room 101  
Chair: Redonna K. Chandler, Ph.D.

Symposium: *Co-Occurring Substance Use and Mental Disorders—Moving the Field Forward*

**8/21 Sun: 12:00 PM–1:50 PM**  
Washington Convention Center, Meeting Room 150A  
Chair: Charlene E. Le Fauve, Ph.D.

## CONFERENCE ANNOUNCEMENT

"We have the pleasure to announce the next International Conference on Monitoring Molecules in Neuroscience to be held in Villasimius (Cagliari, Italy) at the Hotel Timi Ama, on May 19–22, 2006.

This conference is the 11th on In Vivo methods and the 7th with the recurring title of Monitoring Molecules in Neuroscience. We can trace the format of the present conference, as far as regards international attendance and broad covering of the field, to the conference held in Nottingham in 1989 under the organization of Charles Marsden, who also started the In Vivo Methods series in 1982 with a meeting dedicated to electrochemical detection.

The present conference intends to continue the tradition of the previous ones and provide an international stage for new developments and applications in the field of monitoring in vivo the brain chemical state through the assay of specific chemical species and changes.

Among these new developments, in addition to the improvement of established techniques and broadening of their application, is the advent of brain imaging

techniques such as PET. These techniques have often confirmed and extended, in humans, observations initially made in experimental animals with microdialysis and electrochemistry. It is our intention to make sure that the conference will reflect these new developments in the hope that the conference itself would become an obligatory occasion of interaction in the general field of in vivo monitoring of brain's chemical activity.

Given the descent of this conference from the In Vivo Methods series, an important place will be dedicated to new methodological developments. However, as explicitly indicated by the key word 'Neuroscience' in the title, the conference intends to place the in vivo methodological approach in the broad perspective of brain function in health and disease. Because of this, we hope to gather a multidisciplinary audience with a broad interest in basic and clinical Neuroscience." Gaetano Di Chiara (Chair) [info@invivo2006.com](mailto:info@invivo2006.com)

- Elio Acquas  
- Valentina Bassareo

- Cristina Cadoni  
- Ezio Carboni



---

### **Assistant Professor, Department of Pharmacology, University of Mississippi, Oxford**

Applications are invited for a full-time, tenure-track assistant professor position in the Department of Pharmacology in the School of Pharmacy, University of Mississippi (Oxford campus). We seek an individual who will establish and maintain a research program in pharmacology, teach in the core curriculum of the professional and graduate program, and participate in service-related activities. Applicants must have a Ph.D. degree in pharmacology, toxicology, or a closely related field, with postdoctoral experience and a strong record of research accomplishments. High priority areas of research emphasis include molecular pharmacology, neuropharmacology, cardiovascular/autonomic pharmacology, endocrine pharmacology, and environmental toxicology. Exceptional candidates in other research areas will also be considered. Ample opportunities exist for collaborative research programs with members of the National Center for Natural Products Research and the Research Institute of Pharmaceutical Sciences. Visit our Web site at [www.pharmacy.olemiss.edu/pharmacology](http://www.pharmacy.olemiss.edu/pharmacology) for additional information about the research and training programs of faculty in the Department of Pharmacology at the School of Pharmacy.

Applications must be submitted online at [jobs.olemiss.edu](http://jobs.olemiss.edu). Applicants shall provide a letter outlining their research interests, teaching experience and qualifications, complete vitae, and names, addresses, phone numbers, and e-mails of three references. Review of applicants will begin immediately and continue until the position is filled. The anticipated starting date is January 2006. The University of Mississippi is an EEO/AA/Title VI/Title IX/Section 504/ADA/ADEA Employer.

---

### **Mid-Career Investigator, Center for Substance Abuse Research and Policy, Oregon Health and Science University, Portland**

The Center for Substance Abuse Research and Policy within the OHSU Department of Public Health and Preventive Medicine seeks a mid-career investigator with a track record of publication and external funding related to the organization and effectiveness of prevention and treatment services for alcohol and drug use. Opportunities include participation in studies that assess the adoption of buprenorphine, the sustainability of process improvements in the delivery of drug abuse treatment services, and interventions within the National Drug Abuse Treatment Clinical Trials Network. Protocols are conducted in collaboration with a network of treatment programs and a team of investigators and support staff. Travel to study sites and participation in local and national project meetings is required. Publication of papers and presentations at scientific meetings are expected. Current external funding is desirable. Doctoral degree in public health, psychology, or related field with research experience in alcohol and

drug treatment or prevention is required. Salary offered will be appropriate to experience and qualifications and based on external funding. E-mail applications and complete CV to Center Director Dennis McCarty at [mccartyd@ohsu.edu](mailto:mccartyd@ohsu.edu). OHSU posting PDQ\_UPAR663010418.

---

### **Postdoctoral Position, Substance Abuse, University of Arkansas for Medical Sciences, Little Rock**

Research fellowship positions (2-3 yrs) are available in a new and growing research center. Participate in the development, conduct, and publication of studies such as delay discounting, behavioral economics of drug-reinforced behavior, and computerized treatments of drug abuse. Trainees may participate in research using brain-imaging techniques. Outstanding trainees will have opportunity to join the faculty. Applicants must have completed doctoral training in psychology or related field and have research experience. Individuals from disadvantaged groups are encouraged to apply. Competitive stipends. Send letter of interest, vita, and letters of reference to: Warren K. Bickel, Ph.D., Director, Arkansas Center for Addictive Behaviors, University of Arkansas for Medical Sciences, 4301 W. Markham St., # 554, Little Rock, AR 72205.

---

### **Postdoctoral Fellowship, Intramural Research Program, NIDA, Baltimore, Maryland**

The Department of Health and Human Services (DHHS), National Institutes of Health (NIH) is seeking a postdoctoral fellow, to work in the Intramural Research Program (IRP), NIDA. The successful candidate will work in the Psychobiology Laboratory, Medications Discovery Research Branch. We are seeking a highly motivated individual with a Ph.D. in pharmacology, psychology, or neuroscience. Candidates should have experience with the use of whole-animal behavioral techniques, or in vitro techniques for the study of behaviorally active drugs. Surgical skills and background and/or experience with operant conditioning techniques are also desirable. The fellowship is for 2 years, with an optional third year. Candidates may be U.S. citizens, permanent residents, or foreign citizens, and must initially submit a CV and three letters of recommendation (including one from their doctoral thesis advisor) to Jonathan L. Katz, Ph.D., Psychobiology Section, NIDA Intramural Research Program, 5500 Nathan Shock Drive, Baltimore, Maryland, 21224. DHHS and NIH are Equal Opportunity Employers.

---

### **Postdoctoral Position, Human Behavioral Pharmacology of Nicotine, University of Pittsburgh, Pennsylvania**

A postdoctoral position in the behavioral pharmacology of nicotine in humans may be available in the laboratory of Dr. Kenneth A. Perkins at the University of Pittsburgh. This position is funded through NHLBI. Ongoing NIDA-supported projects focus on: 1) environ-

mental modulation of nicotine responses and tobacco self-administration, 2) individual differences associated with sensitivity to nicotine, including gender, genetic, and personality factors. Applicants also interested in clinical research may become involved in smoking cessation studies. Interested candidates should send a C.V. and letter of interest to Kenneth A. Perkins, Ph.D., Department of Psychiatry, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213. Voice: 412-246-5395, fax: 412-246-5390, e-mail: [perkinska@upmc.edu](mailto:perkinska@upmc.edu), Web site: [myprofile.cos.com/perkinsk31](http://myprofile.cos.com/perkinsk31).

---

### **Postdoctoral Research Position, CNS—Neurobehavior Department, Roche Pharmaceuticals, Palo Alto, California**

A postdoctoral research position is available in the CNS—Neurobehavior Department at Roche Pharmaceuticals, Palo Alto, California. This postdoctoral position will establish and validate novel in vivo procedures for Alzheimer's disease and/or cognition. Will characterize and validate multiple behavioral procedures in cognition (i.e., attention, learning, memory, and motivation) using operant/touch screen technology (i.e., CANTAB). Research opportunities will include establishment of multiple cognition paradigms and subsequent validation with standard (i.e., donepezil, memantine) and novel pro-cognitive agents. Will publish results in high-profile, peer-reviewed journals. For further details, please go to: [paloalto.roche.com/careers/jobs/100254.html](http://paloalto.roche.com/careers/jobs/100254.html).

---

### **Three (3) Postdoctoral Positions, Drug Abuse Research, Department of Psychiatry, University of Vermont, Burlington**

The University of Vermont announces the availability of three postdoctoral research fellowships in an internationally recognized center of excellence for the study of drug abuse. Fellows have opportunities for training in a wide range of epidemiological, human laboratory and treatment-outcome research. Current openings are with Stephen Higgins ([stephen.higgins@uvm.edu](mailto:stephen.higgins@uvm.edu), 802-656-9614) in delineating behavioral and pharmacological processes central to understanding and effectively treating cocaine dependence as well as cigarette smoking among pregnant women, and John Hughes ([john.hughes@uvm.edu](mailto:john.hughes@uvm.edu), 802-656-9610) in clinical, laboratory and epidemiology research on (a) gradual reduction with NRT as a method of smoking cessation and (b) understanding why smokers do not access free treatments for smoking cessation. Applicants must have completed doctoral training in psychology or a related discipline and be U.S. citizens or permanent residents. Salary is competitive commensurate with experience (PGY 1 to PGY 7) and supported by an NIDA/NIH Institutional Training Award. For more details on the positions, please contact the investigators directly at the e-mail addresses/phone numbers shown above. To apply please forward a curriculum vitae, statement of



research interests, and three letters of reference in c/o Diana Cain, University of Vermont, Dept. of Psychiatry, 38 Fletcher Place, Burlington, VT 05401-1419. The University of Vermont is an affirmative action and equal opportunity employer.

**Postdoctoral Research Fellowships,  
Substance Abuse Research,  
Johns Hopkins University,  
Baltimore, Maryland**

Postdoctoral research fellowships in

stimulating, productive program with excellent resources. Prepare as independent investigator.

Human Laboratory—behavioral and clinical pharmacology of abused drugs (abuse liability, self-administration, cognitive function, neuro-imaging); anti-drug-abuse medications development. Opioids, cocaine, anxiolytics, alcohol, caffeine, nicotine.

Clinical Trials—testing medications, verbal and behavioral therapies (especially incentive/motivation-based), and combinations; psychiatric comorbidity research; addiction and pregnancy/women. Opioid, cocaine, tobacco,

mixed/other dependencies.

Start Date: Flexible.

Eligibility: citizen, permanent resident. A broad range of backgrounds are appropriate—from clinical/counseling to experimental/neuroscience.

NIH stipend levels: \$35K–51K+.

Contact George Bigelow, Roland Griffiths, or Maxine Stitzer; BPRU, Behavioral Biology Research Center; 5510 Nathan Shock Drive; Johns Hopkins Bayview Campus; Baltimore, Maryland 21224-6823; (410) 550-0035; bigelow@jhmi.edu. See [www.bpru.org](http://www.bpru.org)

## POSTDOCTORAL FELLOWSHIPS, SUBSTANCE ABUSE RESEARCH, UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA

The Department of Psychiatry at the University of Pennsylvania is offering postdoctoral human research fellowships for qualified individuals interested in establishing a career as an independent researcher in the substance abuse field. Postdoctoral fellows have the

opportunity to work and collaborate with established and respected researchers in the field. Opportunities are available to work with investigators in the following: areas of research:

Alcohol Studies	Helen Pettinati, Ph.D., David Oslin, M.D., C. O'Brien, M.D., Ph.D.
Clinical Trials Network	Robert Forman, Ph.D., George Woody, M.D.
Cocaine Studies	Charles Dackis, M.D., Kyle Kampman, M.D.
Brain Imaging/Conditioning	Anna Rose Childress, Ph.D., Ronald Ehrman, Ph.D. Charles O'Brien, M.D., Ph.D, Teri Franklin, Ph.D.
Continuing Care	James McKay, Ph.D.
Evaluation and Assessment	Arthur Alterman, Ph.D., A. Thomas McLellan, Ph.D., James McKay, Ph.D.
Continuing Care	Wade Berrettini, M.D., Ph.D.
Genetics	James Cornish, M.D., Paul J. Fudala, Ph.D.
Medications Development	Julie Blendy, Ph.D., Scott Mackler, M.D. Ph.D.
Molecular biology of stimulant sensitization	Laura Peoples, Ph.D.
Neurophysiology of drug self-administration	Laura McNicholas, M.D., Ph.D.
Opiate Maintenance (Buprenorphine)	
Opiate Studies/Risk factors for HIV and other infections	David Metzger, Ph.D., George Woody, M.D. Edna Foa, Ph.D.
Stress and substance abuse Tobacco	Caryn Lerman, Ph.D., Peter Gariti, Ph.D.

Visit our Center Web site: [www.uphs.upenn.edu/trc/](http://www.uphs.upenn.edu/trc/) to see the range of research and to obtain a fellowship application.

Additional opportunities exist through an affiliation with the Treatment Research Institute. TRI places emphasis upon studies with practical relevance in real-world settings and populations. Specialty areas at TRI include: Adolescents and Family, Criminal Justice, Behavioral Interventions, and Technology Transfer. ([www.tresearch.org](http://www.tresearch.org))

Positions are funded by a NIDA training grant

(Charles P. O'Brien, M.D., PI) and by VA mental health funds. Candidates must have earned a Ph.D., M.D., or equivalent degree prior to the start of the position. Applicants must be U.S. citizens or permanent residents of the United States. Salary is commensurate with experience using NIH and VA scales. Equal Opportunity Employer. Please send curriculum vitae and names of three references to Charles P. O'Brien, M.D., Ph.D., University of Pennsylvania School of Medicine, Center for Studies of Addiction, 3900 Chestnut Street, Philadelphia, PA, 19104-6178.



# DIVISION 28 EXECUTIVE COMMITTEE

---

**ELECTED OFFICERS:**

President  
  
Past President  
President-Elect  
Council Representative  
Members-at-Large

**NAME**

James Zacny  
*jzacny@dacc.uchicago.edu*  
James Sorensen  
Alan Budney  
Maxine Stitzer  
Craig Rush  
Thomas Eissenberg  
Kimberly Kirby

---

**APPOINTED OFFICERS:**

Secretary  
Treasurer  
Newsletter Editor  
Divisional Awards  
Membership  
New Fellows  
Convention Program Chair  
2005  
2006

Drake Morgan  
Jane B. Acri  
John Roll  
Anthony Liguori  
Joshua Lile, *jalile2@uky.edu*  
Suzette Evans  
  
Diana Walker  
Stacey Sigmon

---

**INFORMATION OFFICERS:**

Archivist  
Electronic Information

Richard Foltin  
Ronald W. Wood

---

**COMMITTEE CHAIRS:**

Continuing Education

M. Marlyne Kilbey

---

**APPOINTED LIAISONS/MONITORS:**

Board of Scientific Affairs  
Board of Educational Affairs  
Liaison to Division 50  
Women's Network Representative  
International Relations Committee  
Liaison to CARE  
Student Representative  
Liaison to Scientific Directorate

Marilyn Carroll  
M. Marlyne Kilbey  
Linda Sobell  
Nancy Piotrowski  
Mark Fillmore  
James Rowlett  
Jennifer Perry  
Carl Hart

John M. Roll, Ph.D.  
Assistant Director, Washington Institute for  
Mental Illness Research and Training  
In Charge of Substance Abuse and  
Other Addictive Disorders Research  
Washington State University Spokane  
PO Box 1495  
Spokane, WA 99210-1495